Anorexia Nervosa Overview

An eating disorder is anorexia, also referred to as anorexia nervosa. People who have anorexia restrict their calorie intake and meal choices. They eventually gain weight or are unable to maintain a healthy body weight for their height, age, stature, and physical condition.

“Anorexia Nervosa Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Anorexia Nervosa Market.

The Anorexia Nervosa Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Anorexia Nervosa Pipeline Report:

• Companies across the globe are diligently working toward developing novel Anorexia Nervosa treatment therapies with a considerable amount of success over the years. Anorexia Nervosa Key players such as – Short Wave Pharma, COMPASS Pathways, and others, are developing therapies for the Anorexia Nervosa treatment 

• Anorexia Nervosa Emerging therapies such as – Psychedelics, COMP360, and others are expected to have a significant impact on the Anorexia Nervosa market in the coming years.   
• In August 2022, Compass Pathways initiated a Phase II trial to evaluate efficacy and safety ofCOMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study. This study aims to explore the efficacy and safety of COMP360 25 mg as compared to COMP360 1 mg (control condition) administered with psychological support in participants with Anorexia Nervosa

Route of Administration

Anorexia Nervosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types, such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Anorexia Nervosa Pipeline Therapeutics Assessment

• Anorexia Nervosa Assessment by Product Type
• Anorexia Nervosa By Stage and Product Type
• Anorexia Nervosa Assessment by Route of Administration
• Anorexia Nervosa By Stage and Route of Administration
• Anorexia Nervosa Assessment by Molecule Type
• Anorexia Nervosa by Stage and Molecule Type

DelveInsight’s Anorexia Nervosa Report covers around 3+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Anorexia Nervosa Therapeutics Market include:

Key companies developing therapies for Anorexia Nervosa are – COMPASS Pathways, Biomind Labs, Short Wave Pharma, Artelo Biosciences, AffyImmune Therapeutics, Faron Pharmaceuticals Ltd., Codiak BioScience, Shanghai Henlius Biotech, Taizhou Hanzhong biomedical co. LTD, Merck & Co, Takeda Oncology, and others

Emerging Anorexia Nervosa Drugs Under Different Phases of Clinical Development Include:

• Psychedelics: Short Wave Pharma
• COMP360 : COMPASS Pathways

Get a Free Sample PDF Report to know more about Anorexia Nervosa Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/anorexia-nervosa-pipeline-insight

Anorexia Nervosa Pipeline Analysis:

The Anorexia Nervosa pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Anorexia Nervosa with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Anorexia Nervosa Treatment.
• Anorexia Nervosa key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Anorexia Nervosa Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Anorexia Nervosa market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Anorexia Nervosa product details are provided in the report. Download the Anorexia Nervosa pipeline report to learn more about the emerging Anorexia Nervosa therapies

Anorexia Nervosa Pipeline Market Drivers

• Growing worldwide prevalence

Anorexia Nervosa Pipeline Market Barriers

• Lack of resources/funding
• Guidelines and recommendations are focused on non-pharmacological therapies

Scope of Anorexia Nervosa Pipeline Drug Insight    

• Coverage: Global
• Key Anorexia Nervosa Companies: Short Wave Pharma, COMPASS Pathways, and others
• Key Anorexia Nervosa Therapies: Psychedelics, COMP360, and others
• Anorexia Nervosa Therapeutic Assessment: Anorexia Nervosa current marketed and Anorexia Nervosa emerging therapies
• Anorexia Nervosa Market Dynamics: Anorexia Nervosa market drivers and Anorexia Nervosa market barriers 

Request for Sample PDF Report for Anorexia Nervosa Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Anorexia Nervosa drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting